Roche has doubled down on a partnership with UK biotech Oncimmune looking at how autoantibodies can affect patients’ clinical response to cancer immunotherapies.
NICE has said that Roche’s Tecentriq (atezolizumab) plus chemotherapy should be funded by the NHS as an option for untreated extensive-stage small-cell lung cancer (ES-SCLC) in second draft
NICE has recommended regular NHS funding for Roche’s immunotherapy Tecentriq (atezolizumab) in tough-to-treat advanced triple negative breast cancer in final draft guidance, after a previou
New York biotech Kadmon is on course to file for FDA approval of belumosudil for chronic graft versus host disease (GVHD) after it hit the mark in a pivotal trial.
The FDA has approved AstraZeneca and Merck & Co’s Lynparza (olaparib) in metastatic castration-resistant prostate cancer, just days after the regulator gave the nod for Clovis’ PARP-cla